Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy - Methods & Clinical Development
- Vol. 17, 418-428
- https://doi.org/10.1016/j.omtm.2020.01.013
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases (1P01AI110485-01A1)
- Italian Ministry of Health Ricerca Finalizzata (PE-2011-02347035)
- European Union’s Horizon 2020 (681137)
- European Union’s Seventh Programme for research, technological development and demonstration (280873)
- NIH AIDS Reagent Program
- AIDS Program
- NIAID
- NIH
This publication has 67 references indexed in Scilit:
- SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by VpxNature, 2011
- Profound early control of highly pathogenic SIV by an effector memory T-cell vaccineNature, 2011
- Transduction of Human Antigen-Presenting Cells with Integrase-Defective Lentiviral Vector Enables Functional Expansion of Primed Antigen-Specific CD8+ T CellsHuman Gene Therapy, 2010
- The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturationVirology, 2010
- Integration-deficient Lentiviral Vectors: A Slow Coming of AgeMolecular Therapy, 2009
- Development and use of SIV-based Integrase defective lentiviral vector for immunizationVaccine, 2009
- The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infectionThe Journal of Experimental Medicine, 2009
- Characterization of a myristoylated, monomeric HIV Gag proteinVirology, 2009
- Macaques vaccinated with live-attenuated SIV control replication of heterologous virusThe Journal of Experimental Medicine, 2008
- Different modes and potencies of translational repression by sequence-specific RNA–protein interaction at the 5′-UTRNucleic Acids Research, 2006